Ovarian Cancer

The follow-up results of more than 5 years of the multicenter phase 3 SOLO2 clinical trial of women with ovarian cancer were presented at the 2020 ASCO annual meeting, showing improved survival with the use of Lynparza (olaparib) compared with placebo.

In April 2020, the FDA approved Zejula for long-term maintenance therapy for all patients with advanced ovarian cancer, regardless of any gene mutations.

Julie Silver ran into many “bumps in the road” after she was diagnosed with stage IV ovarian cancer. Despite many difficulties along the way, today her life is filled with gratitude and appreciation.

Here are the drugs and financial support services available to patients receiving treatment for Ovarian Cancer.

Late last year, the PARP inhibitor Zejula was approved by the FDA for patients with HRD mutation associated with advanced ovarian, fallopian tube, or primary peritoneal cancer, offering a new treatment option for women with these types of cancer.

There are a number of excellent organizations providing resources and support to you as a patient with ovarian cancer or a caregiver.

As a retired college professor, Dr. McElhiney uses her personal experience with ovarian cancer to advocate for other patients, urging faster development of new treatment options.

In her Introduction to the special edition of CONQUER titled Understanding Biomarkers & Molecular Testing, Lillie D. Shockney, RN, BS, MAS, ONN-CG, briefly explains what biomarkers are, why they are important, and what you should know about them.